

Alstiphyllanines I-O, ajmaline type alkaloids from *Alstonia macrophylla* showing vasorelaxant activity

by Idha Kusumawati

Submission date: 19-Apr-2021 04:13PM (UTC+0800)

Submission ID: 1563400097

File name: Jurnal_C-17.pdf (583.02K)

Word count: 5959

Character count: 25808



Alstiphyllanines I–O, ajmaline type alkaloids from *Alstonia macrophylla* showing vasorelaxant activity

Hiroko Arai^a, Kazumasa Zaima^a, Erika Mitsuta^a, Haruka Tamamoto^a, Aiko Saito^a, Yusuke Hirasawa^a, Abdul Rahman^b, Idha Kusumawati^b, Noor Cholies Zaini^b, Hiroshi Morita^{a,*}

^a Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142-8501, Japan

^b Faculty of Pharmacy, Airlangga University, Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia

ARTICLE INFO

Article history:

Received 17 March 2012

Revised 4 April 2012

Accepted 6 April 2012

Available online 16 April 2012

Keywords:

Indole alkaloids

Alstonia macrophylla

Alstiphyllanines I–O

Ajmaline type alkaloids

Vasorelaxant activity

Nitric oxide

VDCs

ROCs

SAR

ABSTRACT

Seven new ajmaline type alkaloids, alstiphyllanines I–O (**1–7**) were isolated from the leaves of *Alstonia macrophylla* together with six related alkaloids (**8–13**). Structures and stereochemistry of **1–7** were fully elucidated and characterized by 2D NMR analysis. A series of alstiphyllanines I–O (**1–7**) as well as the known ajmaline type alkaloids (**8–13**) showed that they relaxed phenylephrine (PE)-induced contractions against rat aortic ring. Among them, vincamedine (**10**) showed potent vasorelaxant activity, which may be mediated through inhibition of Ca²⁺ influx through voltage-dependent Ca²⁺ channels (VDCs) and/or receptor-operated Ca²⁺ channels (ROCs) as well as partially mediated the NO release from endothelial cells. The presence of substituents at both N-1 and C-17 may be important to show vasorelaxation activity.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

The vasodilators are useful for treatment of cerebral vasospasm and hypertension, and for improvement of peripheral circulation. Several endothelium-dependent vasodilators, such as bradykinin, acetylcholine, and histamine, have been reported to elevate Ca²⁺ levels in endothelial cells and activate NO release, leading to vasorelaxation.¹ On the other hand, contractile response in smooth muscle is caused by Ca²⁺ influx through VDCs and/or ROCs.² The endothelium-independent vasodilators, such as nicardipine, nifedipine, diltiazem, and verapamil, have been reported to inhibit VDCs and led to decrease the intracellular Ca²⁺ concentration in smooth muscle, leading to vasorelaxation.² K⁺ channels play important roles in the regulation of vascular tone.^{3–5} Indeed, the K⁺ channels present in blood vessels indirectly influence vascular tension by changing the resting membrane potential. Many vascularly active agents and drugs induce their vasodilator or vasoconstrictor effects by opening or closing K⁺ channels.⁶

Our screening study on vasodilators in traditional medicine⁷ discovered that the alkaloidal extract of *Alstonia macrophylla* shows remarkably vasodilation activity against rat aorta. The genus


³³
Alstonia, which is widely distributed in tropical regions of Africa and Asia, are well-known rich sources of unique monoterpene indole alkaloids with various biological activities such as anticancer, antibacterial, anti-inflammatory, antitussive, and antimalarial properties.⁷ Recently, several new indole alkaloids were isolated from extracts of *Alstonia macrophylla* Wall. ex G. Don (Apocynaceae) collected in Indonesia.^{8,9} With an aim to isolate additional new alkaloids showing vasorelaxant activity, purification of extracts of *A. macrophylla* led to seven new alkaloids, alstiphyllanines I–O (**1–7**) together with six known alkaloids (**8–13**). Herein we report the isolation and structure elucidation of alstiphyllanines I–O (**1–7**) as well as vasorelaxant activity and structure–activity relationship (SAR) study of these ajmaline type indole alkaloids.

1.1. Structures of alstiphyllanines I–O (**1–7**)

Leaves of *A. macrophylla* were extracted with MeOH, and the extract was partitioned between EtOAc and 3% aqueous tartaric acid. Water-soluble materials, adjusted to pH 9 with satd aq Na₂CO₃, were extracted with CHCl₃. The CHCl₃-soluble materials were subjected to an LH-20 column (CHCl₃/MeOH, 1:1) followed by a silica gel column (CHCl₃/MeOH, 1:0–0:1). The eluted fractions were further separated by ODS HPLC (MeOH/H₂O/TFA) to afford **1** (5.6 mg, 0.0016% dry weight), **2** (12 mg, 0.0039%), **3** (1.5 mg, 0.0004%), **4**

* Corresponding author. Tel./fax: +81 3 5498 5778.

E-mail address: moritah@hoshi.ac.jp (H. Morita).



(15.2 mg, 0.0029%), **5** (7.2 mg, 0.0021%), **6** (1.5 mg, 0.0004%), and **7** (5.6 mg, 0.0016%), together with six known alkaloids, alstiphyllanine A (**8**),⁹ alstiphyllanine H (**9**),⁹ vincamedine (**10**),¹⁰ vincamajine (**11**),¹¹ vincamajine-17-*O*-veratrate (**12**),¹² and vincamajine-17-*O*-3',4',5'-trimethoxybenzoate (**13**).¹²

Alstiphyllanine I (**1**, [α]_D²⁶ −90 (c 1.0, MeOH)) showed the pseudomolecular ion peak at m/z 559 (M+H)⁺ in the ESIMS, and the molecular formula C₃₂H₃₄N₂O₇, was established by HRESIMS [m/z 559.2455 (M+H)⁺]. IR absorptions implied the presence of carbonyl (1750 and 1670 cm^{−1}) functionalities. The ¹H NMR data (Table 1) showed the presence of four aromatic protons, an ethylidene side chain, a methyl ester, and an acetyl group. The ¹³C NMR data (Table 2) revealed thirty-two carbon signals due to six sp² quaternary carbons, eight sp² methines, two ester carbonyls, one amide carbonyl, two sp³ quaternary carbons, five sp³ methines, three sp³ methylenes, and five methyl groups. Partial structures C-9 to C-12, C-5 to C-6, C-2 to C-15, and C-18 to C-19 were deduced from detailed analysis of the ¹H–¹H COSY spectrum of **1**. The HMBC cross-peaks of H₃-18 to C-20 and H-19 to C-21 placed the ethylidene side chain at C-20. The presence of veratroyl group (δ _C 56.5, 56.5, 112.9, 113.3, 124.1, 127.8, 150.7, and 154.6, respectively) and its connection to a nitrogen atom of the indole ring were elucidated by a HMBC correlation for H'-2 to C-23 (δ _C 170.6). The

HMBC correlations for H-17 to C-5 and C-6 and H-2 to C-17 indicated that **1** was an ajmaline-type alkaloid. The presence of an acetyl group was indicated by the HMBC correlations for H₃-25 and H-17 to C-24 (δ _C 169.9). Thus, **1** was an ajmaline-type alkaloid with a 3,4-dimethoxybenzoyl (veratroyl) group in place of a methyl group of vincamedine.¹⁰ The relative stereochemistry of **1** was elucidated by NOESY correlations as shown in computer-generated 3D drawing (Fig. 1). The NOESY correlations of H₃-18 to H-21 and H-19 to H-15 indicated that the ethylidene side chain was *Z*. In addition, H-3 correlated with both H-2 and H-14a, and H-14b with H-17 indicating that H-2 was α -oriented and H-17 was β -oriented.

Alstiphyllanine J (**2**, [α]_D²⁶ −94 (c 1.0, MeOH)) was revealed to have the molecular formula C₃₃H₃₆N₂O₈, by HRESITOFMS [m/z 589.2548 (M+H)⁺, Δ −0.2 mmu], which was larger than that of alstiphyllanine I (**1**) by CH₂O unit. Compared with ¹H NMR data of **1**, alstiphyllanine J was suggested to be an ajmaline-type backbone with an additional *O*-Me unit at C-5'. The HMBC cross-peak of H₃-*O*-Me (δ _H 3.85) to C-5' (δ _C 155.0) revealed the presence of an eudesmoyl moiety.

HRESITOFMS data [m/z 499.2220 (M+H)⁺, Δ −1.3 mmu] of alstiphyllanine K (**3**, [α]_D²⁶ −20 (c 1.0, MeOH)) established the molecular formula, C₃₀H₃₀N₂O₅, which was smaller than that of alstiphylla-

Table 1
¹H NMR data [δ _H (J, Hz)] of alstiphyllanines I–O (**1**–**7**)

	1 ^a	2 ^a	3 ^a	4 ^a	5 ^a	6 ^a	7 ^a
2	4.38 (m)	4.44 (m)	4.34 (d, 4.8)	4.30 (br s)	4.35 (br s)	4.29 (m)	4.35 (br s)
3	5.19 (m)	5.19 (br s)	4.87 (m)	4.93 (m)	5.09 (m)	4.99 (m)	5.09 (m)
5	4.46 (m)	4.44 (m)	4.09 (m)	4.11 (m)	4.01 (m)	4.15 (m)	4.01 (m)
6a	2.22 (m)	2.31 (d, 9.5)	2.06 (d, 12.3)	2.01 (d, 13.5)	2.10 (dd, 12.4, 6.2)	1.98 (m)	2.10 (dd, 12.4, 6.2)
6b	2.87 (d, 11.0)	2.86 (d, 9.5)	2.79 (dd, 12.3, 3.6)	2.86 (d, 13.5)	2.91 (d, 12.4)	2.88 (d, 11.0)	2.91 (d, 12.4)
9	7.25 (br s)	7.23 (br s)	7.22 (d, 6.6)	7.29 (m)	7.32 (m)	7.32 (d, 6.9)	7.32 (m)
10	7.01 (br s)	7.01 (m)	6.98 (dd, 6.6, 7.8)	7.00 (m)	7.00 (m)	7.01 (dd, 6.9, 8.7)	7.00 (m)
11	7.01 (br s)	7.01 (m)	6.93 (dd, 7.8, 7.8)	6.98 (m)	7.02 (m)	6.93 (dd, 9.0, 8.7)	7.02 (m)
12	6.23 (br s)	6.23 (m)	6.22 (d, 7.8)	6.27 (m)	6.27 (m)	6.11 (d, 9.0)	6.27 (m)
14a	2.08 (t, 14.0)	2.07 (t, 14.0)	1.91 (m)	1.85 (t, 13.9)	1.95 (dd, 14.5, 12.4)	1.91 (t, 14.3)	1.95 (dd, 14.5, 12.4)
14b	2.61 (d, 14.0)	2.59 (d, 14.0)	2.53 (dd, 15.0, 6.0)	2.49 (dt, 13.9, 7.1)	2.55 (dt, 14.5, 4.9)	2.49 (dd, 14.3, 5.0)	2.55 (dt, 14.5, 4.9)
15	3.39 (d, 3.6)	3.37 (br s)	3.24 (m)	3.31 (m)	3.37 (d, 3.6)	3.33 (m)	3.85 (m)
17	6.02 (s)	6.02 (s)	5.96 (s)	4.49 (s)	4.52 (s)	4.50 (s)	4.56 (s)
18	1.61 (d, 6.1)	1.61 (d, 4.5)	1.59 (d, 6.6)	1.59 (d, 6.4)	1.61 (d, 6.6)	1.60 (d, 6.8)	1.67 (d, 6.4)
19	5.60 (m)	5.59 (m)	5.49 (m)	5.50 (m)	5.55 (m)	5.53 (m)	5.55 (m)
21a	4.37 (m)	4.08 (m)	3.84 (m)	3.87 (m)	4.01 (m)	3.92 (m)	4.03 (m)
21b	4.12 (d, 16.0)	4.35 (d, 13.8)	4.09 (m)	4.11 (m)	4.26 (m)	4.18 (m)	4.03 (m)
25	1.91 (s)	1.88 (s)	1.90 (s)				
CO ₂ Me	3.78 (s)	3.78 (s)	3.76 (s)	3.74 (s)	3.76 (s)	3.75 (s)	3.76 (s)
3'- <i>O</i> -Me	3.78 (s)	3.85 (s)		3.74 (s)	3.81 (s)		3.81 (s)
4'- <i>O</i> -Me	3.92 (s)	3.78 (s)		3.82 (s)	3.87 (s)		3.87 (s)
5'- <i>O</i> -Me		3.85 (s)			3.81 (s)		3.81 (s)
2'	7.29 (s)	7.05 (s)	7.74 (d, 7.5)	7.28 (m)	7.01 (s)	7.70 (m)	7.01 (s)
3'			7.52 (dd, 7.6, 7.5)			7.52 (m)	
4'			7.64 (dd, 7.6, 7.6)			7.65 (t, 6.9)	
5'	7.06 (d, 6.9)		7.52 (dd, 7.6, 7.5)	7.02 (d, 6.9)		7.52 (m)	
6'	7.41 (d, 6.9)	7.05 (s)	7.74 (d, 7.5)	7.34 (d, 6.9)	7.01 (s)	7.70 (m)	7.01 (s)

^a TFA salt in CD₃OD.

Table 2
 ^{13}C NMR data (δ_{C}) of alstiphyllanines I–O (1–7)

	1 ^a	2 ^a	3 ^a	4 ^a	5 ^a	6 ^a	7 ^a
2	68.3	68.3	69.0	69.2	69.1	69.4	69.1
3	57.0	57.1	55.9	56.4	57.7	56.8	57.7
5	64.7	64.8	63.8	63.9	64.1	64.6	64.1
6	34.3	34.2	35.7	34.6	34.5	34.9	34.5
7	56.6	57.0	57.5	57.7	57.7	57.9	57.7
8	129.6	129.6	130.9	130.7	131.4	131.7	131.4
9	125.2	125.1	125.2	127.0	127.1	127.2	127.1
10	124.9	125.0	124.7	124.5	124.8	124.7	124.8
11	129.8	129.7	129.4	128.9	129.1	129.0	129.1
12	117.0	117.1	116.9	116.2	116.3	116.4	116.3
13	145.4	145.3	145.5	145.4	145.1	145.0	145.1
14	22.4	22.6	25.5	22.0	21.9	22.8	21.9
15	36.6	36.7	35.7	36.7	36.5	36.5	30.1
16	60.3	61.3	60.7	61.3	61.4	61.9	61.4
17	74.9	74.9	76.1	75.5	75.6	75.6	75.5
18	12.9	12.8	12.6	12.7	12.7	12.7	13.1
19	123.7	123.8	121.2	121.8	122.3	121.9	122.3
20	128.9	128.7	129.8	131.6	129.6	131.3	129.6
21	52.2	52.3	52.7	52.5	52.5	52.5	55.1
22	169.8	170.8	171.9	172.2	172.0	172.3	172.0
23	170.6	170.5	171.9	171.7	171.5	172.1	171.5
24	169.9	169.8	170.3				
25	20.5	20.4	20.6				
CO ₂ Me	53.5	53.4	52.9	52.7	52.6	52.7	52.6
10-O-Me							
3'-O-Me	56.5	61.3		56.9	57.1		57.1
4'-O-Me	56.5	57.0		56.7	61.4		61.4
5'-O-Me		61.3			57.1		57.1
N(1)-Me							
1'	127.8	130.5	136.6	128.7	131.5	136.6	131.5
2'	113.3	107.8	129.8	113.7	108.0	129.6	108.0
3'	150.7	155.0	130.1	150.9	155.1	130.2	155.1
4'	154.6	143.4	133.5	154.6	143.6	133.6	143.6
5'	112.9	155.0	130.1	112.7	155.1	130.2	155.1
6'	124.1	107.8	129.8	124.0	108.0	129.6	108.0

^a TFA salt in CD₃OD.

nine I (**1**) by C₂H₄O₂ unit. The NMR data of **3** were analogous to those of **1** except for the following observation: two methoxy signals (δ_{H} 3.78 and 3.92) in **1** were lack in **3**. The presence of a benzoyl group was verified by the HMBC correlations of H-2' and H-6' to C-23.

Alstiphyllanine L (**4**, [α_{D}^{26} –68 (c 1.0, MeOH)]) was revealed to have the molecular formula C₃₀H₃₂N₂O₆, by HRESITOFMS [m/z 517.2347 (M+H)⁺, Δ +0.8 mmu], which was smaller than that of alstiphyllanine I (**1**) by an acetyl unit. IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.5) supported the presence of a hydroxyl group at C-17.

HRESITOFMS data [m/z 547.2429 (M+H)⁺, Δ –1.5 mmu] of alstiphyllanine M (**5**, [α_{D}^{26} –62 (c 1.0, MeOH)]) established the molecular

formula, C₃₁H₃₄N₂O₇, which was smaller than that of alstiphyllanine J (**2**) by an acetyl unit. IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.6) supported the presence of a hydroxyl group at C-17.

Alstiphyllanine N (**6**, [α_{D}^{26} –62 (c 1.0, MeOH)]) was revealed to have the molecular formula C₂₈H₂₈N₂O₄, by HRESITOFMS [m/z 457.2132 (M+H)⁺, Δ +0.5 mmu], which was smaller than that of alstiphyllanine K (**3**) by an acetyl unit. IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.6) supported the presence of a hydroxyl group at C-17.

Alstiphyllanine O (**7**, [α_{D}^{26} –53 (c 1.0, MeOH)]) had a molecular formula C₃₁H₃₄N₂O₇ based on the HRESITOFMS [m/z 547.2429 (M+H)⁺, Δ –1.5 mmu]. The IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.5) supported the presence of a hydroxyl group at C-17. Analysis of the ¹H, ¹³C, and 2D NMR of **7** gave the same planar structure as **5**, suggesting that **7** should be a stereoisomer of **5**. The NOESY correlation of H-15/H₃-18 indicated that the ethylidene side chain was *E*.

A detail 2D NMR analysis of a series of alstiphyllanines J–O (**2**–**7**) suggested their structures were related ajmaline-type indole alkaloids. The relative stereochemistry of a series of alstiphyllanines J–O (**2**–**7**) was elucidated by NOESY correlations. The NOESY correlation of H₃-18 to H-21 and H-19 to H-15 indicated that the geometry of ethylidene side chain was *Z* except for that of alstiphyllanine O. The NOESY correlations of H-3/H-2 and H-14a and H-14b/H-17 indicated that H-2 was α -orientated and H-17 was β -orientated.

1.2. Vasorelaxant activity in ex-vivo

All isolated compounds except for **3** (it is not enough for evaluation because of the limited amount) were tested for vasorelaxant activity against rat aorta (Fig. 2). When PE (0.3 μM) was applied to thoracic aortic rings with endothelium after achieving a maximal response, a series of alstiphyllanines I, J, L–O (**1**, **2**, **4**–**7**) and their related ajmaline-type alkaloids, alstiphyllanine A (**8**), alstiphyllanine H (**9**), vincamedine (**10**), vincamajine (**11**), vincamajine-17-*O*-veratrate (**12**), and vincamajine-17-*O*-3',4',5'-trimethoxybenzoate (**13**), were added and some of them showed potent vasorelaxant effects at 30 μM (Fig. 2). The presence of a hydroxy group at C-17 and an N(4)-oxide reduced the potency of vasodilation. On the other hand, the presence of substituents at N(1) might affect slightly on vasorelaxant activity. In addition, compared with the geometry at C-19 of **5** and **7**, 19Z might increase the potency of vasodilation.

Vincamedine (**10**) showed the excellent activity at early stage within 5–15 min after addition. Furthermore, to investigate the involvement of endothelial cells, vasorelaxant activity was tested using endothelium-denuded aorta (–EC rings) for **10** (Fig. 3).




Figure 1. Selected 2D NMR correlations for alstiphyllanine I (**1**).




Figure 2. Relaxation responses induced by isolated compounds (1, 2, 4–13) at 30 μ M on the rat aortic rings precontracted with 0.3 μ M phenylephrine. Values are the mean \pm S.D. ($n = 3$).




Figure 3. Concentration-dependent relaxation by **10** in +EC or –EC rings precontracted with PE (A). Vasorelaxant effect of **10** on +EC rings precontracted with PE in the presence or absence of L-NMMA (B). Values are the mean \pm S.E.M. ($n = 3$) * $P < 0.05$ and ** $P < 0.01$ respectively, versus +EC group.

Compound **10** caused concentration-response relaxation with maximum response at 100 μ M in +EC rings (Fig. 3). The relaxation induced by **10** was partly attenuated in –EC rings and in the presence of N^G -monomethyl-L-arginine (L-NMMA, 100 μ M), an inhibitor of nitric oxide synthase (NOS), suggesting that effects induced by **10** partially mediated the NO release from endothelial cells (Fig. 3). However, vasorelaxant effect of **10** on –EC rings still remained. Hence, subsequent investigations were focused on the direct effect of **10** on vascular smooth muscle cells using –EC rings.

To investigate the involvement of K^+ channel, the vasorelaxant effect of **10** in PE-contracted –EC rings was examined by pretreatment of tetraethylammonium chloride [TEA (nonselective large-conductance Ca^{2+} -activated K^+ channel (BK_{Ca}) inhibitor). The concentration-dependent response was not altered by TEA (Fig. 4), which suggested that vasorelaxant effect of **10** did not involve K^+ channel.

Cumulative addition of isotonic high- K^+ (10–80 mM) elicits a concentration-dependent contraction by Ca^{2+} influx via VDC. High K^+ -induced contractile response was significantly decreased by pretreatment of **10** (Fig. 5). Therefore, the relaxant effect of **10** was thought to be due to inhibitory effect on VDC-dependent Ca^{2+} influx.

In addition, we investigated the involvement of ROC. After pretreatment with PE and nicardipine in Ca^{2+} -free modified Krebs–Henseleit solution (KHS), the contractile response induced by $CaCl_2$ showed dose-dependent manner from 10 μ M to 1 mM, presum-





Figure 4. Vasorelaxant effect of **10** on PE-precontracted –EC rings in the presence or absence of TEA. Values are the mean \pm S.E.M. ($n = 3$)



32

Figure 5. Concentration–response curves for isotonic high K^+ -induced contractions in –EC rings in the presence or absence of **10**. Values are the mean \pm S.E.M. ($n=3$) * $P<0.05$ versus control group.




Figure 6. Effect of **10** on $CaCl_2$ -induced contraction of –EC rings pretreated with PE and nifedipine in Ca^{2+} -free medium. Values are the mean \pm S.E.M. ($n=3$) * $P<0.05$, ** $P<0.01$, and *** $P<0.001$ respectively, versus control group.

ably due to the influx of Ca^{2+} via ROC. The addition of **10** significantly inhibited $CaCl_2$ -induced contraction dependent on ROC, suggesting that **10** also has inhibitory effect on Ca^{2+} influx via ROC (Fig. 6).

In conclusion, we isolated seven new ajmaline type alkaloids, alstiphyllanines I–O (**1–7**) from the leaves of *Alstonia macrophylla* together with six related alkaloids (**8–13**). Structures and stereochemistry of **1–7** were fully elucidated and characterized by 2D NMR analysis. A series of alstiphyllanines I–O (**1–7**) as well as the known ajmaline type alkaloids (**8–13**) showed that they relaxed PE-induced contractions against rat aortic ring. The presence of a hydroxy group at C-17 and an $N(4)$ -oxide reduced the potency of vasodilation. On the other hand, the presence of substituents at $N(1)$ and the geometry at C-19 might affect slightly on vasorelaxation activity. Among them, vincamedine (**10**) showed potent vasorelaxant activity, which may be mediated through inhibition of Ca^{2+} influx through VDCs and/or ROCs as well as partially mediated the NO release from endothelial cells.

2. Experimental section

20

2.1. General methods

1H and 2D NMR spectra were recorded on a Bruker AV 400 spectrometer and chemical shifts were reported using residual CD_3OD (δ_H 3.31 and δ_C 49.0) as internal standards. Standard pulse sequences were employed for the 2D NMR experiments. 1H – 1H COSY, HOHAHA, and NOESY spectra were measured with spectral widths

of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 t_1 increments. NOESY spectra in the phase sensitive mode were measured with a mixing time of 800 ms. For HMQC spectra in the phase sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1 K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

2.2. Material

The leaves of *Alstonia macrophylla* were collected at Nglipay, East Java, Indonesia in 2008. The botanical identification was made by Ms. Sri Wuryanti, Purwodadi Botanical Garden, Indonesia. A voucher specimen has been deposited in the herbarium at Purwodadi Botanical Garden, Pasuruan, Indonesia.

2.3. Extraction and isolation

The leaves of *A. macrophylla* (900 g) were extracted with MeOH to give the extract (154 g). The MeOH extract (59 g) was treated with 3% tartaric acid (pH 2) and then partitioned with EtOAc. The aqueous layer was treated with satd aq Na_2CO_3 aq to pH 9 and extracted with $CHCl_3$ to give alkaloidal fraction (2.0 g). The alkaloidal fraction was purified by LH-20 column ($CHCl_3/MeOH$, 1:0) and SiO_2 column ($CHCl_3/MeOH$, 1:0–0:1) and the fractions eluted by $CHCl_3/MeOH$ (50:1 to 20:1) were purified by ODS HPLC (59–61% MeOH with 0.1% CF_3CO_2H ; flow rate, 2 mL/min; UV detection at 254 nm) to afford alstiphyllanines I (**1**, 5.6 mg, 0.0016% dry weight), J (**2**, 12 mg, 0.0039%), K (**3**, 1.5 mg, 0.0004%), L (**4**, 15.2 mg, 0.0029%), M (**5**, 7.2 mg, 0.0021%), N (**6**, 1.5 mg, 0.0004%), and O (**7**, 1.5 mg, 0.0004%), together with six known alkaloids, alstiphyllanine A (**8**),⁹ alstiphyllanine H (**9**),⁹ vincamedine (**10**),¹⁰ vincamajine (**11**),¹¹ vincamajine-17-*O*-veratrate (**12**),¹² and vincamajine-17-*O*-3',4',5'-trimethoxybenzoate (**13**).¹²

2.3.1. Alstiphyllanine I (1)

Brown amorphous solid; $[\alpha]_D^{26} -90$ (c 1.0, MeOH); IR (film) ν_{max} 1750 and 1670 cm^{-1} ; UV (MeOH) λ_{max} 297 (ϵ 9600), 276 (11,300), 217 (24,700) and 202 (30,900) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 559 (M+H)⁺; HRESITOFMS m/z 559.2455 [(M+H)⁺, Δ +1.1 mmu, calcd for $C_{32}H_{35}N_2O_7$, 559.2444].

2.3.2. Alstiphyllanine J (2)

Brown amorphous solid; $[\alpha]_D^{26} -94$ (c 1.0, MeOH); IR (film) ν_{max} 1750 and 1680 cm^{-1} ; UV (MeOH) λ_{max} 293 (ϵ 9600), 277 (ϵ 35,800), 219 (5000), and 201 (10,600) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 589 (M+H)⁺; HRESITOFMS m/z 589.2548 [(M+H)⁺, Δ –0.2 mmu, calcd for $C_{33}H_{37}N_2O_8$, 589.2550].

2.3.3. Alstiphyllanine K (3)

Brown amorphous solid; $[\alpha]_D^{26} -20$ (c 1.0, MeOH); IR (film) ν_{max} 1750 and 1680 cm^{-1} ; UV (MeOH) λ_{max} 293 (ϵ 1900), 268 (2400), 219 (5000) and 201 (10,600) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 499 (M+H)⁺; HRESITOFMS m/z 499.2220 [(M+H)⁺, Δ –1.3 mmu, calcd for $C_{30}H_{31}N_2O_5$, 499.2233].

2.3.4. Alstiphyllanine L (4)

Brown amorphous solid; $[\alpha]_D^{26} -68$ (c 1.0, MeOH); IR (film) ν_{max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{max} 286 (ϵ 8400), 273 (9200), 220 (21,700) and 202 (37,300) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 517 (M+H)⁺; HRESITOFMS m/z 517.2347 [(M+H)⁺, Δ +0.8 mmu, calcd for $C_{30}H_{33}N_2O_6$, 517.2339].

2.3.5. Alstiphyllanine M (5)

Brown amorphous solid; $[\alpha]_D^{26} -62$ (c 1.0, MeOH); IR (film) ν_{\max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{\max} 293 (ϵ 9200), 273 (15,000), 213 (41,100) and 202 (62,500) nm; ^1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 547 (M+H) $^+$; HRESITOFMS m/z 547.2429 [(M+H) $^+$], $\Delta -1.5$ mmu, calcd for $\text{C}_{31}\text{H}_{35}\text{N}_2\text{O}_7$, 547.2444].

2.3.6. Alstiphyllanine N (6)

Brown amorphous solid; $[\alpha]_D^{26} -62$ (c 1.0, MeOH); IR (film) ν_{\max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{\max} 291 (ϵ 6300), 271 (8800), 218 (11,100) and 202 (49,100) nm; ^1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 457 (M+H) $^+$; HRESITOFMS m/z 457.2132 [(M+H) $^+$], $\Delta +0.5$ mmu, calcd for $\text{C}_{28}\text{H}_{29}\text{N}_2\text{O}_4$, 457.2127].

2.3.7. Alstiphyllanine O (7)

Brown amorphous solid; $[\alpha]_D^{26} -53$ (c 1.0, MeOH); IR (film) ν_{\max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{\max} 293 (ϵ 9200), 271 (15,000), 218 (41,100) and 202 (62,500) nm; ^1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 547 (M+H) $^+$; HRESITOFMS m/z 547.2429 [(M+H) $^+$], $\Delta -1.5$ mmu, calcd for $\text{C}_{31}\text{H}_{35}\text{N}_2\text{O}_7$, 547.2444].

2.4. Vasodilation assay¹³

The thoracic aorta between the aortic arch and the diaphragm was harvested from a male Wistar rat weighting 260 g and placed in oxygenated, modified KHS (118.0 mM NaCl, 4.7 mM KCl, 25.0 mM NaHCO_3 , 1.8 mM CaCl_2 , 1.2 mM NaH_2PO_4 , 1.2 mM MgSO_4 , and 11.0 mM glucose). After removing loosely adhering fat and connective tissue, the aorta was cut into ring preparations 3 mm in length. The aorta was placed in bath filled well-oxygenated (95% O_2 , 5% CO_2) KHS at 37 °C with connection to a force-displacement transducer (Nihon Kohden, TB-611T, Tokyo, Japan). The aorta ring was equilibrated for 60 min under a resting tension of 1.0 g.

After equilibration, each aorta ring was contracted by treatment with PE (0.3 μM). Aortic rings with 80% relaxation by acetylcholine (ACh, 10 μM) were regarded as endothelium-intact aorta (+EC rings). Following washout, these rings were contracted once again with the same concentration of PE. When the PE-induced contraction reached a plateau, each sample (30 μM) or ACh (1 nM–10 μM) was added cumulatively. IC_{50} of ACh (positive control) was approximately 1 μM in this experimental system.

To test for the involvement of endothelium-dependency in relaxation response, the endothelial cells were removed by rubbing and were confirmed by observing the loss of ACh-induced relaxation (–EC rings). When PE-induced contractions reached a plateau, vincamedine (**10**) was added cumulatively.

To test for the involvement of K^+ channel, TEA (1 mM; nonselective large-conductance Ca^{2+} -activated K^+ channel (BK_{Ca}) inhibitor) was applied to the aortic rings 30 min prior to precontraction by PE. Cumulative concentration-response of **10** was compared with or without TEA.

To investigate the involvement of VDC in the vasorelaxant response by **10**, aortic rings were equilibrated in KHS for 60 min. Ca^{2+} -free high K^+ solution (10–80 mM as KCl) was then added for observation of contractile response (control). When maximum contraction was achieved, the ring was washed and equilibrated for 60 min. After pretreatment of **10** at 30 μM for 30 min, Ca^{2+} -free high K^+ solution was added once again. A KCl-induced contractile response with or without each sample was compared.

To clarify the involvement of ROC-dependent Ca^{2+} influx, a contractile response induced by Ca^{2+} was recorded twice. Firstly, aortic rings were equilibrated in Ca^{2+} -free KHS with 0.01 mM EGTA for 60 min. After pretreatment with nicardipine (1 μM) for 30 min and following PE-prestimulation, aorta ring was contracted by cumulative addition of CaCl_2 (10 μM –1 mM). After the confirmation of maximum contraction, the ring was washed and equili-

brated for 60 min to carry out second contractile experiment. Vincamedine (**10**) was added before PE-stimulation, and Ca^{2+} -induced contractile response was recorded as same as first contractile experiment. These two contractile responses by Ca^{2+} with/without **10** were evaluated.

All tested compounds were dissolved in DMSO and diluted with saline. The final concentration of DMSO in the organ bath was less than 0.1%, and did not show any effects on contraction or relaxation. All other drugs were dissolved in saline.

All results are expressed as means \pm S.E.M. Statistical analysis was done by Student's paired or unpaired *t*-test. $P < 0.05$ was considered statistically significant.

These animal experimental studies were conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University and under the supervision of the Committee on Animal Research of Hoshi University, which is accredited by the Ministry of Education, Science, Sports Culture, and Technology of Japan.

Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and a Grant from The Open Research Center Project in Hoshi University.

References and notes

- Muller, J. M.; Davis, M. J.; Kuo, L.; Chilian, W. M. *Am. J. Physiol.* **1999**, *276*, H1706–H1714; Muller, B.; Kleschyov, A. V.; Gyorgy, K.; Stoclet, J. C. *Physiol. Res.* **2000**, *49*, 19–26.
- Karaki, H.; Ozaki, H.; Hori, M.; Mitsui-Saito, M.; Amano, K.; Harada, K.; Miyamoto, S.; Nakazawa, H.; Won, K. J.; Sato, K. *Pharmacol. Rev.* **1997**, *49*, 157.
- Faraci, F. M.; Heistad, D. D. *Physiol. Rev.* **1998**, *78*, 53–97.
- Standen, N. B.; Quayle, J. M. *Acta Physiol. Scand.* **1998**, *164*, 549–577.
- Tanaka, Y.; Koike, K.; Toro, L. J. *Smooth Muscle Res.* **2004**, *40*, 125–153.
- Shieh, C. C.; Coghlan, M.; Sullivan, J. P.; Gopalakrishnan, M. *Pharmacol. Rev.* **2000**, *52*, 557–594.
- Monita, H.; Iizuka, T.; Choo, C. Y.; Chan, K. L.; Itokawa, H.; Takeya, K. *J. Nat. Prod.* **2005**, *68*, 1686; Monita, H.; Eda, M.; Iizuka, T.; Hirasawa, Y.; Sekiguchi, M.; Yun, Y. S.; Itokawa, H.; Takeya, K. *Bioorg. Med. Chem. Lett.* **2006**, *17*, 4458–4461; Monita, H.; Enomoto, M.; Hirasawa, Y.; Iizuka, T.; Ogawa, K.; Kawahara, N.; Goda, Y.; Matsumoto, T.; Takeya, K. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5410–5413; Monita, H.; Tomizawa, Y.; Deguchi, J.; Ishikawa, T.; Arai, H.; Zaima, K.; Hosoya, T.; Hirasawa, Y.; Matsumoto, T.; Kamata, K.; Ekasari, W.; Widyawaruyanti, A.; Wahyuni, T. S.; Zaini, N. C.; Honda, T. *Bioorg. Med. Chem.* **2009**, *17*, 8234–8240; Hirasawa, Y.; Hara, M.; Nugroho, A. E.; Sugai, N.; Zaima, K.; Kawahara, N.; Goda, Y.; Awang, K.; Hadi, A. H. A.; Morita, H. *J. Org. Chem.* **2010**, *75*, 4218–4223; Matsumoto, T.; Kobayashi, T.; Ishida, K.; Hirasawa, Y.; Morita, H.; Honda, T.; Kamata, K. *Bio. Pharm. Bull.* **2010**, *33*, 844–848; Matsuo, H.; Okamoto, R.; Zaima, K.; Hirasawa, Y.; Ismail, I. S.; Lajis, N. H.; Morita, H. *Bioorg. Med. Chem.* **2011**, *19*, 4075–4079; Zaima, K.; Takeyama, Y.; Koga, I.; Saito, A.; Tamamoto, H.; Azziz, S. S. S. A.; Mukhtar, M. R.; Awang, K.; Hadi, A. H. A.; Morita, H. *J. Nat. Med.*, in press.; Zaima, K.; Deguchi, J.; Matsuno, Y.; Kaneda, T.; Hirasawa, Y.; Morita, H. *J. Nat. Med.*, in press.; Zaima, K.; Koga, I.; Iwasawa, N.; Hosoya, T.; Hirasawa, Y.; Kaneda, T.; Ismail, I. S.; Lajis, N. H.; Morita, H. *J. Nat. Med.*, in press.
- (a) Kamarajan, P.; Sekar, N.; Mathuram, V.; Govindasamy, S. *Biochem. Int.* **1991**, *25*, 491–498; (b) Saraswathi, V.; Subramanian, S.; Ramamoorthi, N.; Mathuram, V.; Govindasamy, S. *Med. Sci. Res.* **1997**, *25*, 167–170; (c) Keawpradub, N.; Kirby, G. C.; Steele, J. C. P.; Houghton, P. J. *Planta Med.* **1999**, *65*, 690–694; (d) Husain, K.; Jantan, I.; Kamaruddin, N.; Said, I. M.; Aimi, N.; Takayama, H. *Phytochemistry* **2001**, *57*, 603–606; (e) Husain, K.; Jantan, I.; Said, I. M.; Aimi, N.; Takayama, H. *J. Asian Nat. Prod. Res.* **2003**, *5*, 63–67; (f) Jagetia, G. C.; Baliga, M. S. *Phytother Res.* **2006**, *20*, 103–109; (g) Khan, M. R.; Omoloso, A. D.; Kihara, M. *Fitoterapia* **2003**, *74*, 736–740; (h) Gupta, R. S.; Bhatnager, A. K.; Joshi, Y. C.; Sharma, M. C.; Khushalani, V.; Kachhawa, J. B. *Pharmacology* **2005**, *75*, 57–62.
- Hirasawa, Y.; Arai, H.; Zaima, K.; Oktařina, R.; Rahman, A.; Ekasari, W.; Indrayanto, G.; Zaini, N.; Morita, H. *J. Nat. Prod.* **2009**, *72*, 304–307; Arai, H.; Hirasawa, Y.; Rahman, A.; Ekasari, W.; Zaini, N.; Sato, S.; Aoyama, C.; Takeo, J.; Monita, H. *Bioorg. Med. Chem.* **2010**, *18*, 2152–2158.
- Caron, C.; Yachouli, Y.; Massiot, G.; Men-Olivier, L.; Puset, J.; Sevenet, T. *Phytochemistry* **1984**, *23*, 2355–2357.
- Ratnayake, C.; Arambewela, L.; Silva, K.; Rahman, A.; Alvi, K. *Phytochemistry* **1975**, *14*, 1849–1854.
- Abe, F.; Yamauchi, T.; Santisuk, T. *Phytochemistry* **1994**, *37*, 249–252.
- Monita, H.; Iizuka, T.; Choo, C. Y.; Chan, K. L.; Takeya, K.; Kobayashi, J. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4609–4611.

Alstiphyllanines I-O, ajmaline type alkaloids from *Alstonia macrophylla* showing vasorelaxant activity

ORIGINALITY REPORT

15%

SIMILARITY INDEX

5%

INTERNET SOURCES

13%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

- 1 Morita, H.. "Structure of a new cyclic nonapeptide, segetalin F, and vasorelaxant activity of segetalins from *Vaccaria segetalis*", *Bioorganic & Medicinal Chemistry Letters*, 20060901
Publication 1%
- 2 Kobayashi, Jun'ichi, Kazutaka Shimbo, Masaaki Sato, and Masashi Tsuda. "Amphidinolides H2-H5, G2, and G3, New Cytotoxic 26- and 27-Membered Macrolides from Dinoflagellate *Amphidinium* sp.", *The Journal of Organic Chemistry*, 2002.
Publication 1%
- 3 Ozawa, Masaaki, Shunsuke Kawamata, Tadahiro Etoh, Masahiko Hayashi, Kanki Komiyama, Akio Kishida, Chiaki Kuroda, and Ayumi Ohsaki. "Structures of New Erythrinan Alkaloids and Nitric Oxide Production Inhibitors from *Erythrina crista-galli*", *CHEMICAL & PHARMACEUTICAL BULLETIN*, 2010. 1%

4

Katsuo Kamata. "Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes", *British Journal of Pharmacology*, 06/1999

Publication

1 %

5

Takaaki Kubota, Masashi Tsuda, Yukiko Doi, Ayako Takahashi et al. "Luteophanols B and C, new polyhydroxyl compounds from marine dinoflagellate *Amphidinium* sp.", *Tetrahedron*, 1998

Publication

1 %

6

Naoko Kuzumaki, Daigo Ikegami, Rie Tamura, Takuya Sasaki et al. "Hippocampal epigenetic modification at the doublecortin gene is involved in the impairment of neurogenesis with aging", *Synapse*, 2010

Publication

1 %

7

Morita, H.. "Antimitotic activity of glaupalol-related coumarins from *Glaucidium palmatum*", *Bioorganic & Medicinal Chemistry Letters*, 20040716

Publication

1 %

8

www.j3.jstage.jst.go.jp

Internet Source

1 %

9

Ayako Makino, Shu-Ichi Oda, Katsuo Kamata.
"Mechanisms underlying increased release of
endothelin-1 from aorta in diabetic rats",
Peptides, 2001

Publication

10

Mario Figueroa, María del Carmen González,
Rogelio Rodríguez-Sotres, Alejandro Sosa-
Peinado et al. "Calmodulin inhibitors from the
fungus Emericella sp.", Bioorganic & Medicinal
Chemistry, 2009

Publication

11

Kaniwa, K.. "Kehokorins A-C, novel cytotoxic
dibenzofurans isolated from the myxomycete
Trichia favoginea var. persimilis", Tetrahedron
Letters, 20060306

Publication

12

Edwin Risky Sukandar, Sutin Kaennakam,
Kitiya Rassamee, Pongpun Siripong, Sri
Fatmawati, Taslim Ersam, Santi Tip-pyang.
"Xanthones and biphenyls from the stems of
Garcinia cylindrocarpa and their cytotoxicity",
Fitoterapia, 2018

Publication

13

repository.um.edu.my

Internet Source

14

www.thieme-connect.com

Internet Source

<1 %

<1 %

<1 %

<1 %

<1 %

<1 %

15 Hiroshi Suenaga, Yutaka Kasuya, Katsuo Kamata. "GTP-Binding protein regulates the contractile response elicited by the phorbol ester (PMA)-induced activation of protein kinase C in the isolated rat aorta", General Pharmacology: The Vascular System, 1996
Publication

<1 %

16 Wenxin Xue. "Effects of Taurine on Aortic Rings Isolated from Fructose-fed Insulin Resistance Sprague–Dawley Rat are Changed", Cardiovascular Drugs and Therapy, 12/2008
Publication

<1 %

17 linknovate.com
Internet Source

<1 %

18 Qin, S.. "Suffruticosine, a novel octacyclic alkaloid with an unprecedented skeleton from Securinegasuffruticosa (Pall.) Rehd.", Tetrahedron Letters, 20081201
Publication

<1 %

19 pure.uva.nl
Internet Source

<1 %

20 Afifa Bergaoui, Saoussen Hammami, Hichem Ben Jannet, Zine Mighr. " Echiofruzine, a novel naringenin diglycoside from growing in Tunisia ", Natural Product Research, 2007
Publication

<1 %

21 Micah Reynolds. "Cytotoxic diterpenoids from Podocarpus madagascariensis from the Madagascar rainforest†", Natural Product Research, 5/20/2006
Publication

22 Angela A. Salim, Mary J. Garson, David J. Craik. " New Indole Alkaloids from the Bark of ", Journal of Natural Products, 2004
Publication

23 pubs.rsc.org
Internet Source

24 www.theses.fr
Internet Source

25 www.tandfonline.com
Internet Source

26 Ratchanee Phatchana, Yordhathai Thongsri, Chavi Yenjai. "Canangalias C-H, juvenile hormone III analogues from the roots of Cananga latifolia", Fitoterapia, 2016
Publication

27 Yong Li, Ya-Tuan Ma, Yi Kuang, Jin-Ming Gao, Jian-Chun Qin. "Pecipamide, a New Sphingosine Derivative from the Cultures of Polyporus picipes (Basidiomycetes)", Lipids, 2010
Publication

28

pubmed.ncbi.nlm.nih.gov

Internet Source

<1 %

29

Katsuo Kamata. "Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats", *British Journal of Pharmacology*, 09/2000

Publication

<1 %

30

academicjournals.org

Internet Source

<1 %

31

Joanne Soon-Yee Yeap, Chun-Hoe Tan, Kien-Thai Yong, Kuan-Hon Lim, Siew-Huah Lim, Yun-Yee Low, Toh-Seok Kam. "Macroline, talpinine, and sarpagine alkaloids from *Alstonia penangiana*. An NMR-based method for differentiating between *A. penangiana* and *A. macrophylla*", *Phytochemistry*, 2020

Publication

<1 %

32

Takayuki Matsumoto, Keisuke Takayanagi, Mihoka Kojima, Kumiko Taguchi, Tsuneo Kobayashi. "Mechanisms underlying suppression of noradrenaline-induced contraction by prolonged treatment with advanced glycation end-products in organ-cultured rat carotid artery", *Pflügers Archiv - European Journal of Physiology*, 2020

Publication

<1 %

33

Xiang-Hai Cai. "A Cage-Monoterpene Indole Alkaloid from *Alstonia scholaris*", *Organic Letters*, 02/2008

Publication

<1 %

34

Wei Wang, Ming-He Cheng, Xiao-Hua Wang. "Monoterpenoid Indole Alkaloids from *Alstonia rupestris* with Cytotoxic, Anti-Inflammatory and Antifungal Activities", *Molecules*, 2013

Publication

<1 %

35

Yoshio Tanaka, Toshiyasu Imai, Tomomi Igarashi, Kazuyuki Takayanagi et al. "Comparison of the Ca²⁺ entry channels responsible for mechanical responses of guinea-pig aorta to noradrenaline and thapsigargin using SK&F 96365 and LOE 908", *Naunyn-Schmiedeberg's Archives of Pharmacology*, 2000

Publication

<1 %

36

berkalahayati.org

Internet Source

<1 %

37

K.-E. Andersson. "Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction", *Pharmacological Reviews*, 2011

Publication

<1 %

38

Sarot Cheenpracha, Thunwadee Ritthiwigrom, Surat Laphookhieo. " Alstoniaphyllines A–C, Unusual Nitrogenous Derivatives from the Bark of ", *Journal of Natural Products*, 2013

Publication

<1 %

39

digitalcommons.georgefox.edu

Internet Source

<1 %

40

Ji-Zheng Sun. "A new kalihinol diterpene from the Hainan sponge *Acanthella* sp.", *Archives of Pharmacal Research*, 11/2009

Publication

<1 %

41

Kyo Bin Kang, Gao Ming, Geum Jin Kim, Thi-Kim-Quy Ha, Hyukjae Choi, Won Keun Oh, Sang Hyun Sung. "Jubanines F–J, cyclopeptide alkaloids from the roots of *Ziziphus jujuba*", *Phytochemistry*, 2015

Publication

<1 %

42

Masashi Tsuda, Takuma Sasaki, Jun'ichi Kobayashi. "Hymenamides G, H, J, and K, four new cyclic octapeptides from the Okinawan marine sponge *Hymeniacidon* sp.", *Tetrahedron*, 1994

Publication

<1 %

43

Katsuo Kamata. "Lysophosphatidylcholine potentiates vascular contractile responses in rat aorta via activation of tyrosine kinase", *British Journal of Pharmacology*, 02/2002

Publication

<1 %

44

Keiichi Shimamura. "TENSION OSCILLATION
IN ARTERIES AND ITS ABNORMALITY IN
HYPERTENSIVE ANIMALS", Clinical and
Experimental Pharmacology and Physiology,
4/1999

Publication

<1 %

Exclude quotes Off

Exclude matches Off

Exclude bibliography On

Alstiphyllanines I-O, ajmaline type alkaloids from *Alstonia macrophylla* showing vasorelaxant activity

GRADEMARK REPORT

FINAL GRADE

/0

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6
